Seropositive Rheumatoid Arthritis Drug Market Research Report Information By Drug Class (Nsaid, Dmards, Biologics), Treatment (Synovectomy, Tendon Repair, Joint Fusion), Diagnosis, Drug, Application, Route Of Administration, End User – Global Forecast Till 2030

Seropositive Rheumatoid Arthritis Drug Market Scenario:

The Seropositive Rheumatoid Arthritis Drug Market is expected to reach at 7.20% CAGR during the forecast period 2022-2030.Arthritis means inflammation in a joint. The inflammation is characterized by swelling, pain, and redness within the joint. This type of arthritis is known to cause chronic inflammatory disorder in the hands and feet.

There are two types of rheumatoid arthritis are seronegative rheumatoid arthritis and seropositive rheumatoid arthritis. Smoking and family history are considered as some of the major cause of rheumatoid arthritis.

The rising R&D of product pipeline along with the introduction of novel products are some of the major trends in this market. For instance, in February 2016, Pfizer received FDA approval for commercialization of XELJANZ XR (tofacitinib citrate) in the U.S. market. The company launched the product in Europe for the treatment of rheumatoid arthritis. In May 2017, Sanofi received FDA approval for Kevzara drug for its commercialization in the U.S. market. Kevzara is used in the treatment of active rheumatoid arthritis.

The seropositive rheumatoid arthritis drug market is expected to be driven by factors such as rising cigarette consumption, growing healthcare expenditure, increasing female population, and increasing obese population. However, the growth of this industry is hindered by increasing treatment costs and high cost associated with R&D. The seropositive rheumatoid arthritis drug market is rather concentrated with few pharmaceutical companies dominating the market through new drug approval.

The seropositive rheumatoid arthritis drug market is expected to grow at a CAGR of approximately 4.0% during the forecast period 2017-2023.

Intended Audience

• Seropositive Rheumatoid Arthritis Drug Suppliers


• Seropositive Rheumatoid Arthritis Drug Manufacturers


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Academic Medical Institutes and Universities

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation

Segmentation

The seropositive rheumatoid arthritis drug market is segmented on the basis of the drug class, drug, treatment and diagnosis, route of administration, application, and end user.

On the basis of the drug class, the seropositive rheumatoid arthritis drug market is segmented into Non-steroidal anti-inflammatory drug type (NSAID), Steroids, and Disease-modifying anti-rheumatic drug type (DMARDs) and biologic agents.

On the basis of the drug, the seropositive rheumatoid arthritis drug market is segmented into Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Rituxan (rituximab), Actemra (tocilizumab), Orencia (abatacept), and others.

On the basis of the treatment, the seropositive rheumatoid arthritis drug market is segmented into synovectomy, tendon repair, joint fusion, and total joint replacement.

On the basis of the diagnosis, the seropositive rheumatoid arthritis drug market is segmented into C -reactive protein (CRP) Test, CCP, ESR (Erythrocyte Sedimentation Rate) Test and Synovial Fluid Analysis.

On the basis of the route of administration, the seropositive rheumatoid arthritis drug market is segmented into oral, subcutaneous, intravenous, and others.

On the basis of the application, the seropositive rheumatoid arthritis drug market is segmented into medicine, scientific research, and others.

On the basis of the end user, the seropositive rheumatoid arthritis drug market is segmented into hospital, diagnostic centers, ambulatory surgical centers, and others

Regional Analysis

The seropositive rheumatoid arthritis drug market is segmented into the Americas, Europe, Asia Pacific and the Middle East and Africa.

The Americas dominated the overall market in terms of revenue in 2016 owing to the growing prevalence of arthritis, and rising cases of inflammation in the U.S.

Europe is the second largest rheumatoid market in the globe. The U.K is a major contributor to the European market. As per the National Rheumatoid Arthritis Society (NRAS), it was estimated that approximately 690,000 people suffer from rheumatoid arthritis in the U.K. Moreover, the government bodies are undertaking initiatives for the spreading awareness regarding rheumatoid arthritis is influencing the market growth.

The Asia Pacific is expected to be the fastest growing region, which accounts for more than 60% of the global population. The region has the potential to provide great opportunities for researchers to analyze the pathogenesis, epidemiology, and the factors that influence various manufacturers for expansion and setting up their manufacturing unit in this region.

The Middle East & Africa region contribute the least share of the seropositive rheumatoid arthritis market owing to the low R&D activities, lack of awareness, and poor medical facilities.

Key Players

Some of key the players in the seropositive rheumatoid arthritis drug market are Abbott Laboratories (U.S.),  Johnson & Johnson Limited (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen (U.S.), Vertex Pharmaceuticals Incorporated (U.S), Sanofi-Aventis (France), AstraZeneca (U.K), Cadila Healthcare Ltd. (India), GlaxoSmithKline Inc. (U.S.), Merck and Co. Inc. (U.S.), and others